Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective vigilantly but unsuccessfully to develop a single therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past few shares. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set out all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very promotional picture in the Uptick Newswire job interview that I came away with a poor viewpoint of the business.

Irony of irony, my poor impression of the company has grown steadily, although the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the therapy and avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of this technology as well as associated intellectual property from Progenics to CytoDyn, and approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) as well as the very first brand new drug program approval ($5 million), and even royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and numerous indications, it’s this single treatment and a “broad pipeline of indications” because it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an active organization with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple publications in addition to multiple presentations.

Can all this be smoke and mirrors? That’s a question I’ve been asking myself with the really start of the interest of mine in this particular company. Judging with the multiples of thousands of diverse comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a classic battleground, or perhaps some may say cult stock. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *